系统性红斑狼疮（SLE）是一种慢性自身免疫性疾病，被称为"不死的癌症""蝴蝶病"。港大深圳医院风 湿免疫科在学科带头人张丽君主任的带领下，自2013年开设系统性红斑狼疮专病门诊以来，打造了一套 覆盖预防、检查、诊断及治疗全周期标准化模式，近两年狼疮专病年就诊量高达4000人次。科室积累了 丰富的救治重症狼疮患者的经验。张丽君表示，国家级示范中心落户港大深圳医院，既是对科室既往工 作的高度认可，也寄托了业界对医院未来发展的深切期许。 据了解，此次全国仅11家单位获此授牌，该院是深圳市首家通过该项认证的医疗机构，标志着深圳乃至 粤港澳大湾区及周边区域在自身免疫性疾病诊疗领域，迈入标准化、协同化发展的新阶段。 港大深圳医院副院长白明珠表示："此次揭牌，不仅是医院和风湿免疫科的喜事，更是响应国家号召， 推动优质医疗资源下沉、提升区域诊疗规范化水平的重要实践。未来，我们将肩负起标杆责任，凝练可 复制、可推广的'深港经验'，服务湾区患者。" 【深圳商报讯】（记者 赵鸿飞 通讯员 港深医信）近日，香港大学深圳医院举行揭牌活动，该院风湿免 疫科获评国家皮肤与免疫疾病临床医学研究中心"系统性红斑狼疮（SLE）规范化诊治示范中心 ...

近年来，国际上对于系统性红斑狼疮临床研究取得突飞猛进的新发展，并获得了突出成果，一些生物制 剂的合并使用，为系统性红斑狼疮患者带来了新希望。作为全国首家"港澳药械通"试点单位，港大深圳 医院关注患者需求，已通过"港澳药械通"政策成功引进国际创新药物阿伏利尤单抗，为中度至重度活动 性、自身抗体阳性系统性红斑狼疮成人患者提供了新的治疗选择。 阿伏利尤单抗是全球首个且唯一获批的靶向Ⅰ型干扰素通路的系统性红斑狼疮治疗靶向药物，研究证实 其对红斑狼疮具有良好的疗效和安全性。能够改善患者临床表现，降低疾病活动度，减少疾病复发，同 时有助于改善生物学指标（如补体水平、血清抗体等），帮助患者实现更好的疾病预后。 持续深化风湿免疫学科建设，强化示范中心的辐射带动作用 12月25日，香港大学深圳医院（以下简称"港大深圳医院"）学科建设系列活动国家"规范化诊治中心-系 统性红斑狼疮示范中心"揭牌活动举行。港大深圳医院风湿免疫科获评国家皮肤与免疫疾病临床医学研 究中心"系统性红斑狼疮（SLE）规范化诊治示范中心"。此次全国仅11家单位获此授牌，港大深圳医院 是深圳市首家通过该项认证的医疗机构，也是广东省内屈指可数的入选单位，这一荣誉 ...

Group 1: Company Developments - AstraZeneca (AZ) showcased its dominance at the ASCO annual meeting, marking its seventh consecutive year on the main stage and has been selected for eight LBA studies since 2020, particularly excelling in lung and breast cancer while making significant strides in gastrointestinal tumors [1] - In recent years, AZ has made strategic acquisitions to enhance its position in cell therapy, including the purchase of Neogene in 2022 for TCR-T therapy, a partnership with Quell in 2023 for Treg therapy, and a $1 billion acquisition of EsoBiotec, focusing on in vivo cell therapy [1][9] - The acquisition of Gengxi Biotech is highlighted as a pivotal move for AZ in the CAR-T space, with promising data emerging from its clinical trials, particularly for AZD0120 in treating refractory systemic lupus erythematosus (rSLE) and newly diagnosed multiple myeloma (NDMM) [2][6][9] Group 2: Clinical Data and Efficacy - AZD0120 has shown positive safety and preliminary efficacy in a study involving 10 rSLE patients, with 100% of patients normalizing complement levels and 70% achieving sustained serological remission [3][5] - In NDMM, AZD0120 demonstrated a 100% overall response rate (ORR) and a 95.5% stringent complete response (sCR) rate in high-risk transplant-eligible patients, with a median follow-up of 32.3 months [6][8] - For elderly patients with NDMM, AZD0120 also achieved a 100% ORR and sCR rate, indicating its potential as a new treatment option for patients over 70 years old [7][8] Group 3: Market Potential and Future Outlook - The global market for multiple myeloma (MM) drugs is projected to reach $43.7 billion by 2028 and $52.1 billion by 2033, highlighting the significant opportunity for AZD0120 if it can secure a position in first-line treatment [8] - AZD0120 is positioned as a key asset in AZ's cell therapy portfolio, with expectations for it to drive growth beyond 2030, especially following its recent clinical successes [8][9] - The strategic focus on Shanghai as a research hub for cell therapy underlines AZ's commitment to leveraging China's innovative capabilities to enhance its global cell therapy development [9]